Fusion Antibodies update regarding COVID-19 business continuity.
Posted onUpdate on the Coronavirus / COVID-19 situation.
News
The challenges of phage display for affinity maturation
Posted onAt Fusion Antibodies, our rational affinity maturation platform sidesteps most of the issues with phage display. Our rationally designed in silico libraries are magnitudes larger than phage libraries, with around 10^25 variants.
Fusion Antibodies Collaborates with Queen’s University on Knowledge Transfer Partnership Programme
Posted onThe new programme will allow for the development of an innovative software solution for the design of antibody libraries.
In silico – the future of antibody development
Posted onLearn more about how in silico technology accelerates antibody design and development, which reduces costs.
Fusion Antibodies form strategic collaboration with E2DG to provide end-to-end service for oncology drug discovery companies.
Posted onThe two companies will work together to deliver a seamless service offering for clients from discovery to manufacturing and PoC preclinical and phase I & II design and execution.